8 recruiting, 3 active not recruiting, 3 completed, 3 not yet recruiting. 20 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Recruiting 8, Active not recruiting 3, Completed 3, Not yet recruiting 3, Terminated 2, Unknown 1 |
| Phase 1 | 5 | Recruiting 4, Terminated 1 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Transurethral Resection of Bladder: new trials by email Literature Review of Transurethral Resection of Bladder trials Research Report on Transurethral Resection of Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer Cyclophosphamide, Fludarabine, Aldesleukin (IL-2) - Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Beth Israel Deaconess Medical Center | 10 | 2027-04-26 | 2026-11-09 |
| Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer Trastuzumab Rezetecan, Adebrelimab, Concurrent Bladder Radiotherapy - Muscle-Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | Tongji Hospital | 70 | 2026-09-01 | 2026-10-08 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | 114 | 2026-08-01 | 2026-08-10 |
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-26 |
| DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma DOC1021, Tumor resection, pIFN (peginterferon alfa-2a) - Refractory Melanoma | Phase 1 / Phase 2 | Recruiting | Diakonos Oncology Corporation | 35 | 2026-04-06 | 2026-09-09 |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2025-11-25 | 2026-11-03 |
| NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment Active Surveillance, Control arm - Definitive bladder treatment - Muscle-Invasive Bladder Carcinoma | Phase 2 / Phase 3 | Recruiting | Peter Black | 688 | 2025-07-28 | 2025-07-30 |
| Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT) - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 47 | 2025-03-31 | 2026-10-01 |
| DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) DOC1021, Tumor resection, Temodar (Temozolomide) - Glioblastoma (GBM) | Phase 2 | Recruiting | Diakonos Oncology Corporation | 180 | 2025-03-17 | 2026-07-01 |
| Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Biospecimen Collection, Cyclophosphamide, Echocardiography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Completed | University of Kansas Medical Center | 11 | 2023-12-21 | 2026-04-30 |
| Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy - Urinary Bladder Neoplasms | Phase 2 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 65 | 2023-02-01 | 2022-12-28 |
| Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 161 | 2020-03-18 | 2026-11-12 |
| Niraparib/TTFields in GBM Niraparib, Optune, Planned surgical resection - Glioblastoma, Recurrent Glioblastoma | Phase 2 | Active not recruiting | Abramson Cancer Center at Penn Medicine | 30 | 2019-12-30 | 2026-01-08 |
| Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery Cetuximab, Cetuximab-IRDye 800CW, Tumor resection - Brain Neoplasm, Malignant Glioma | Phase 1 / Phase 2 | Terminated | Eben Rosenthal | 3 | 2016-10-01 | 2020-03-31 |
| Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Pembrolizumab, Transurethral Resection of Bladder Tumor, Gemcitabine - Muscle-invasive Urothelial Cancer of the Bladder | Phase 2 | Completed | NYU Langone Health | 60 | 2016-08-11 | 2026-09-30 |
| A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Proton Therapy, Surgery - Craniopharyngioma | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 160 | 2016-06-22 | 2026-09-22 |
| Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) Methotrexate, Vinblastine, Doxorubicin - Urothelial Carcinoma of the Bladder | Phase 2 | Completed | Fox Chase Cancer Center | 78 | 2016-02-24 | 2026-05-22 |
| Chemoradiation in Locally Advanced Pancreatic Cancer recombinant interferon alfa, cisplatin, fluorouracil - Pancreatic Cancer | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 23 | 2005-01-01 | 2017-12-28 |
Urinary Bladder Neoplasms (7) · Glioblastoma (3) · Brain Neoplasms (2) · Glioma (2) · Melanoma (2) · Astrocytoma (1) · Carcinoma (1) · Carcinoma, Renal Cell (1) · Craniopharyngioma (1) · Kidney Neoplasms (1) · Laryngeal Neoplasms (1) · Lymphoma, Follicular (1) · Mouth Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Oligodendroglioma (1)
National Cancer Institute (NCI) (3) · Diakonos Oncology Corporation (2) · Abramson Cancer Center at Penn Medicine (1) · Beth Israel Deaconess Medical Center (1) · Eben Rosenthal (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Fox Chase Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Mayo Clinic (1) · NYU Langone Health (1) · Peter Black (1) · St. Jude Children's Research Hospital (1) · Tianjin Medical University Second Hospital (1) · Tongji Hospital (1) · University of California, San Francisco (1)
United States (16) · China (3) · Canada (1) · Guam (1) · Puerto Rico (1)
David Einstein, MD (1) · Eben Rosenthal, MD (1) · Edward W. Greeno, MD (1) · Gordon Li, MD (1) · Jinhai Fan, MD (1) · Leslie Ballas (1) · Matin Imanguli (1) · Michael E Woods (1) · Minas Economides, MD (1) · Muhammad Umair Mushtaq (1) · Peter Black, MD (1) · Shaogang Wang (1) · T. Martin Ma, MD, PhD (1) · Terence C. Burns, MD, PhD (1) · Thomas E. Merchant, DO, PhD (1)
PMID 33607632, PMID 33660142, PMID 39680823, PMID 40343719, PMID 41959823, PMID 42567733
P30CA124435 (1), P30CA168524 (1), U10CA180821 (1), U10CA180888 (1), UM1CA186691 (1)